In an average adult without severe insulin resistance or other glucose‑lowering medications, how much will a 6‑unit subcutaneous dose of rapid‑acting insulin (lispro, aspart, or glulisine) lower blood glucose and affect ketone concentrations?

Glucose and Ketone Response to 6 Units of Rapid‑Acting Insulin

In an average adult without severe insulin resistance, a single 6‑unit subcutaneous dose of rapid‑acting insulin (lispro, aspart, or glulisine) typically lowers blood glucose by approximately 180–300 mg/dL over 3–5 hours, with the peak effect occurring 1–3 hours post‑injection; however, ketone reduction is minimal with a single correction dose and requires sustained insulin coverage to suppress ongoing ketogenesis.

Glucose‑Lowering Effect of 6 Units

• The insulin sensitivity factor (ISF) for an individual is calculated as 1500 ÷ total daily insulin dose (TDD); for example, a patient with a TDD of 50 units has an ISF of 30 mg/dL per unit, meaning each unit of rapid‑acting insulin lowers glucose by approximately 30 mg/dL. 1
• Applying this formula, 6 units of rapid‑acting insulin would lower blood glucose by roughly 180 mg/dL (6 × 30) in a patient with moderate insulin sensitivity. 1
• In patients with lower insulin resistance (e.g., TDD of 30 units), the ISF is 50 mg/dL per unit (1500 ÷ 30), so 6 units would lower glucose by approximately 300 mg/dL. 1
• Conversely, in patients with higher insulin resistance (e.g., TDD of 100 units), the ISF is 15 mg/dL per unit (1500 ÷ 100), so 6 units would lower glucose by only 90 mg/dL. 1

Pharmacokinetic Profile of Rapid‑Acting Insulins

• Insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, with peak levels occurring 30–90 minutes after injection and a duration of activity of less than 5 hours. 2
• Insulin aspart and insulin lispro produce similar serum insulin levels (250–300 pmol/L) at approximately 30 minutes and disappear from serum after approximately 4 hours, with indistinguishable effects on glucose and fat metabolism. 3
• Insulin glulisine displays an absorption profile with a peak insulin concentration approximately twice that of regular human insulin, reached in approximately half the time, with an onset of action at 0.25–0.5 hours, peak action at 1–3 hours, and duration of 3–5 hours. 4
• Fast‑acting insulin aspart provides earlier onset, doubling of initial exposure, and an up to 2.5‑fold increase in initial glucose‑lowering effect within 30 minutes of subcutaneous injection compared with standard insulin aspart. 5

Ketone Reduction with a Single Correction Dose

• A single 6‑unit correction dose of rapid‑acting insulin has minimal direct effect on ketone clearance because ketone suppression requires sustained insulin coverage to inhibit lipolysis and ketogenesis over several hours. 6
• In diabetic ketoacidosis (DKA), continuous intravenous regular insulin infusion at 0.1 units/kg/hour is required to clear ketones, with resolution criteria including β‑hydroxybutyrate < 1.0 mmol/L, bicarbonate ≥ 18 mEq/L, and pH > 7.3. 6
• Effects on lipid metabolism (plasma free fatty acid, ketone body levels, and free fatty acid oxidation) appear to peak earlier (at approximately 2 hours) and disappear earlier (after approximately 4 hours) than the effects on carbohydrate metabolism with rapid‑acting insulins. 3
• Premature discontinuation of insulin is the most common cause of recurrent DKA, underscoring that ketone clearance requires continuous insulin therapy rather than intermittent correction doses. 6

Factors Influencing Individual Response

• Body weight and insulin resistance significantly affect insulin sensitivity; patients with higher insulin resistance require more insulin per unit of glucose reduction. 1
• Time of day influences insulin sensitivity, with morning hours often requiring more insulin per gram of carbohydrate due to counter‑regulatory hormones like cortisol and growth hormone. 1
• Physical activity level impacts insulin sensitivity, with exercise increasing insulin sensitivity and requiring less insulin to lower glucose. 1
• The insulin sensitivity factor should be recalculated periodically, such as during illness or changes in physical activity patterns, to maintain accurate dosing. 1

Clinical Application and Monitoring

• For a patient with a pre‑meal glucose of 250 mg/dL, a simplified correction scale recommends 2 units of rapid‑acting insulin; for glucose > 350 mg/dL, 4 units are recommended, always in addition to scheduled prandial doses. 1
• Correction insulin must supplement a scheduled basal‑bolus regimen and should never be used as monotherapy; sliding‑scale insulin alone achieves target glucose in only ≈38 % of patients versus ≈68 % with scheduled basal‑bolus therapy. 1
• Recheck glucose 1–2 hours after the correction dose to assess response and avoid "stacking" correction doses, as insulin from the previous dose may still be active. 1
• If correction doses consistently fail to bring glucose into target range, adjust the ISF rather than the basal dose, and avoid giving rapid‑acting insulin at bedtime as a sole correction dose due to markedly increased nocturnal hypoglycemia risk. 1

Ketone Management Requires Sustained Insulin

• In patients with type 1 diabetes or insulin dependence, check urine or blood ketones immediately if glucose exceeds 250 mg/dL with symptoms (nausea, vomiting, abdominal pain, or altered mental status) to identify early diabetic ketoacidosis. 6
• Serum β‑hydroxybutyrate measurement is preferred over urine ketone testing because it reflects real‑time ketone clearance; urine ketones may lag and give a false impression of ongoing ketosis. 6
• Continuous IV insulin infusion is required for DKA resolution, with insulin maintained until serum ketones fall below 1.0 mmol/L, regardless of normalized glucose, to suppress ongoing ketogenesis. 6
• A single subcutaneous correction dose of 6 units will not resolve established ketosis; patients with persistent ketones require basal insulin coverage plus correction doses to achieve sustained ketone suppression. 6